Immunomet Therapeutics

Biotech targeting cellular metabolism for novel anti-cancer and anti-fibrosis therapies

placeHouston, Texas, United States calendar_todayFounded 2015 groups9 employees language immunomet.com

Innovation

19 patent families (12 granted) — focus: Chemistry & metallurgy, Human necessities; filing pace slowing. Cited 819 times.

YearFilings
20167
20178
20187
20195
20207
20215
20223
20235
20242
20252
20261

Investor mix

6 investors on record; lead investors include Mirae Asset Venture.

Investor typeCountShare
Venture capital467%
Accelerator & incubator117%
Other / undisclosed117%
Coming soon